This, together with the presence of higher levels of CD38 at intermediate stages of maturation of pre-GC B-cells, (which was also more pronounced in CVID group 2 patients), may reflect delayed maturation of immature B-cells to mature naive B-lymphocytes among this subgroup of CVID patients. The gene discussed is CD38; the disease is common variable immunodeficiency.